Home / Expertise / Life Sciences & Healthcare

Life Sciences & Healthcare

Switzerland

Our Life Sciences & Healthcare team consists of specialised attorneys who will advise and represent you in all legal matters competently and tailored to the special needs of your company. 

With more than 300 lawyers specialising in the Life Sciences & Healthcare sector worldwide and the support of the Life Sciences Asia Pacific Network (LAN), we at CMS are very familiar with the economic, commercial and legal needs of our clients in those industries.

Reputation

We have been working successfully for many years with leading companies in the Life Sciences sector in the fields of pharmaceuticals, medical devices, biotechnology, chemistry, foodstuffs and cosmetics. These include the world’s most important pharmaceutical companies and the world’s leading medical device companies. In the Healthcare sector, we advise and represent all relevant medical service providers (hospitals, HMOs, nursing homes, laboratories, physicians, pharmacists, etc.) and their associations.

Comprehensive advice and representation

We regularly advise our Life Sciences clients on their day-to-day business, for example in:

  • Research and development (particularly in clinical trials)
  • Patent enforcement
  • Regulatory authorisations
  • Advertising and distribution issues
  • Pricing strategies and reimbursements under social security law
  • Compliance
  • Data protection

We support our Healthcare clients in particular in the areas of:

  • Social security regulatory authorisations
  • Professional law
  • Data protection
  • Tariff negotiations and tariff settings
  • Planning (hospital planning, planning of highly-specialised medicine)
  • Liability issues and compliance

Whether you require professional support in the area of contracts, strategic agreements or in competition and antitrust law, or an expert opinion, are planning a corporate transaction or seek to engage in legal proceedings or are affected by legal, administrative or criminal proceedings, we would be delighted to assist you.

Industry knowledge

Many of our experts have worked in Life Sciences & Healthcare companies prior to joining CMS, gaining extensive knowledge in pharmaceuticals, medical devices, biotechnology, chemistry, foodstuffs, cosmetics and medical services. Through our active membership in the most important industry associations and our participation in the legislative process, we contribute to shaping the legal and regulatory framework for the Life Sciences & Healthcare sector.


Find out more in our Life Sciences & Healthcare brochure

Read more Read less

'Due to very good networking', CMS 'can provide know-how in a variety of matters', especially at a multi-jurisdictional level. Regulatory, compliance, financial benefits and pricing advice, as well as the negotiation of agreements and representation in court form the main areas of expertise.

The Legal 500, Healthcare and life sciences, Switzerland, 2019
Life Sci­ences & Health­care Prac­tice Group Switzer­land

Feed

Show only
08 Jul 19
CMS ad­vises Bruker on the ac­quis­i­tion of PMOD Tech­no­lo­gies...
15 Nov 19
Brexit and data pro­tec­tion: what to do next (when you don’t know what’s...
Whilst the threat of a no-deal Brexit has been aver­ted for now, the fu­ture is by no means cer­tain. We have high­lighted some of the key is­sues for UK-based or­gan­isa­tions, and the EEA or­gan­isa­tions that...
26/04/2019
CMS once again one of the lead­ing law firms in Switzer­land
BIL­ANZ Rank­ing 2019
05 Nov 19
Whis­tleblow­ing Dir­ect­ive ad­op­ted by the EU Coun­cil
On 7 Oc­to­ber 2019, the EU Coun­cil ap­proved the word­ing of the "Dir­ect­ive of the European Par­lia­ment and of the Coun­cil on the pro­tec­tion of per­sons who re­port breaches of Uni­on law", also known as the...
16 Apr 19
CMS Switzer­land fur­ther im­proves its rank­ing with The...
13 Sep 19
SPC Double Whammy - In­ter­pret­ing Art­icle 3(a) of the SPC Reg­u­la­tion
Sum­mary At the end of June, the CJEU heard the joint re­fer­rals from the Ger­man Bundes­pat­ent­gericht (case C-650/17) for Mer­ck’s sitaglipt­in product and from the Eng­lish Court of Ap­peal for Searle’s...
03 Apr 19
CMS ad­vises Op­tim­apharm Group on the ac­quis­i­tion of...
30 May 19
EPO's strict ap­proach to de­cid­ing if a com­pos­i­tion can be­ne­fit from...
The EPO Tech­nic­al Board of Ap­peal (TBA) re­viewed the law around nov­elty of use, and de­term­ined that in the case of Car­di­oPoly­mer, Inc.'s European pat­ent ap­plic­a­tion (EP07837908.8), the claimed chem­ic­al...
27 Feb 19
CMS ad­vised Syn­cona Ltd on in­vest­ment in Ana­ve­on AG
27 Mar 19
Judg­ment on Ab­rax­is C-443/17; 21st March 2019
The CJEU de­livered its judg­ment last week on the case of Ab­rax­is v Comp­troller Gen­er­al of Pat­ents con­cern­ing Sup­ple­ment­ary Pro­tec­tion Cer­ti­fic­ates (SPCs) for new for­mu­la­tions of medi­cin­al products. The...
Dec 2018
CMS Life Sci­ences & Health­care Sec­tor Group: An over­view...
24 Aug 18
Gov­ern­ment Is­sues Brexit Tech­nic­al No­tice for Life Sci­ences
On 23 Au­gust 2018, the UK Gov­ern­ment (the "Gov­ern­ment") is­sued the first wave of its tech­nic­al pa­pers de­signed to provide guid­ance to com­pan­ies to help pre­pare for a "No Deal" Brexit. In this scen­ario,...